サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1434553

抗菌薬市場：投与経路、薬剤クラス別、流通チャネル-2024～2030年の世界予測

Antibacterial Drugs Market by Routes of Administration (Enteral, Parenteral), Drug Class (Aminoglycoside, B ? Lactams, Macrolides), Distribution Channel - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 195 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
抗菌薬市場：投与経路、薬剤クラス別、流通チャネル-2024～2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗菌薬市場規模は2023年に376億3,000万米ドルと推計され、2024年には391億5,000万米ドルに達し、CAGR 4.12%で2030年には499億4,000万米ドルに達すると予測されます。

抗菌薬の世界市場

主な市場の統計
基準年[2023］ 376億3,000万米ドル
予測年[2024] 391億5,000万米ドル
予測年 [2030] 499億4,000万米ドル
CAGR（%） 4.12%
抗菌薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは抗菌薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、抗菌薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-抗菌薬市場の市場規模および予測は？

2-抗菌薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-抗菌薬市場における技術動向と規制の枠組みは？

4-抗菌薬市場における主要ベンダーの市場シェアは？

5-抗菌薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 感染症の蔓延
      • 新しい抗菌薬の承認とリリースの増加
      • ジェネリック医薬品の普及
    • 抑制要因
      • 抗菌薬の特許が切れる
    • 機会
      • 有効性が向上し、薬に伴う副作用が少ないいくつかの新規化合物の革新
      • 新興国における抗菌薬の採用
    • 課題
      • 多剤耐性菌株の存在
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 抗菌薬市場投与経路別

  • 経腸
  • 非経口

第7章 抗菌薬市場薬剤クラス別

  • アミノグリコシド
  • B-ラクタム
  • マクロライド系
  • フェニコール
  • キノロン類
  • スルホンアミド
  • テトラサイクリン

第8章 抗菌薬市場：流通チャネル別

  • ドラッグストアおよび小売薬局
  • 病院薬局
  • オンライン薬局

第9章 南北アメリカの抗菌薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の抗菌薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの抗菌薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Allecra Therapeutics GmbH
    • Allergan PLC
    • AstraZeneca PLC
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Debiopharm Group
    • Eli Lilly and Company
    • Entasis Therapeutics by Innoviva, Inc.
    • GlaxoSmithKline PLC
    • Iterum Therapeutics PLC
    • Johnson & Johnson Services Inc.
    • Kyorin Pharmaceutical Co., Ltd.
    • Melinta Therapeutics LLC
    • Merck & Co., Inc.
    • Sanofi-Aventis Groupe S.A.
    • Teva Pharmaceutical Industries Ltd.
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ANTIBACTERIAL DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBACTERIAL DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTIBACTERIAL DRUGS MARKET DYNAMICS
  • FIGURE 7. ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 8. ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 10. ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ANTIBACTERIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ANTIBACTERIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTIBACTERIAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBACTERIAL DRUGS MARKET SIZE, BY ENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTIBACTERIAL DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 9. ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTIBACTERIAL DRUGS MARKET SIZE, BY B - LACTAMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTIBACTERIAL DRUGS MARKET SIZE, BY PHENICOLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG STORES & RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTIBACTERIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ANTIBACTERIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. ANTIBACTERIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 148. ANTIBACTERIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. ANTIBACTERIAL DRUGS MARKET LICENSE & PRICING
目次
Product Code: MRR-4358BACA8014

[195 Pages Report] The Antibacterial Drugs Market size was estimated at USD 37.63 billion in 2023 and expected to reach USD 39.15 billion in 2024, at a CAGR 4.12% to reach USD 49.94 billion by 2030.

Global Antibacterial Drugs Market

KEY MARKET STATISTICS
Base Year [2023] USD 37.63 billion
Estimated Year [2024] USD 39.15 billion
Forecast Year [2030] USD 49.94 billion
CAGR (%) 4.12%
Antibacterial Drugs Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antibacterial Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibacterial Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antibacterial Drugs Market, highlighting leading vendors and their innovative profiles. These include Allecra Therapeutics GmbH, Allergan PLC, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Debiopharm Group, Eli Lilly and Company, Entasis Therapeutics by Innoviva, Inc., GlaxoSmithKline PLC, Iterum Therapeutics PLC, Johnson & Johnson Services Inc., Kyorin Pharmaceutical Co., Ltd., Melinta Therapeutics LLC, Merck & Co., Inc., Sanofi-Aventis Groupe S.A., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Antibacterial Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Routes of Administration
    • Enteral
    • Parenteral
  • Drug Class
    • Aminoglycoside
    • B - Lactams
    • Macrolides
    • Phenicols
    • Quinolones
    • Sulfonamide
    • Tetracycline
  • Distribution Channel
    • Drug Stores & Retail Pharmacies
    • Hospital Pharmacies
    • Online Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antibacterial Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibacterial Drugs Market?

3. What are the technology trends and regulatory frameworks in the Antibacterial Drugs Market?

4. What is the market share of the leading vendors in the Antibacterial Drugs Market?

5. Which modes and strategic moves are suitable for entering the Antibacterial Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Antibacterial Drugs Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of infectious diseases
      • 5.1.1.2. Increasing approval and launch of new antibacterial drugs
      • 5.1.1.3. Widespread of the generic drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Patent expiry of the antibacterial drug
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovation in some novel compounds with improved efficacy, and fewer side effects associated with the drugs
      • 5.1.3.2. Adoption of antibacterial drugs in emerging countries
    • 5.1.4. Challenges
      • 5.1.4.1. Presence of multi-drug resistant bacterial strains
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Antibacterial Drugs Market, by Routes of Administration

  • 6.1. Introduction
  • 6.2. Enteral
  • 6.3. Parenteral

7. Antibacterial Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Aminoglycoside
  • 7.3. B - Lactams
  • 7.4. Macrolides
  • 7.5. Phenicols
  • 7.6. Quinolones
  • 7.7. Sulfonamide
  • 7.8. Tetracycline

8. Antibacterial Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Drug Stores & Retail Pharmacies
  • 8.3. Hospital Pharmacies
  • 8.4. Online Pharmacies

9. Americas Antibacterial Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antibacterial Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antibacterial Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Allecra Therapeutics GmbH
    • 13.1.2. Allergan PLC
    • 13.1.3. AstraZeneca PLC
    • 13.1.4. Bayer AG
    • 13.1.5. Bristol-Myers Squibb Company
    • 13.1.6. Debiopharm Group
    • 13.1.7. Eli Lilly and Company
    • 13.1.8. Entasis Therapeutics by Innoviva, Inc.
    • 13.1.9. GlaxoSmithKline PLC
    • 13.1.10. Iterum Therapeutics PLC
    • 13.1.11. Johnson & Johnson Services Inc.
    • 13.1.12. Kyorin Pharmaceutical Co., Ltd.
    • 13.1.13. Melinta Therapeutics LLC
    • 13.1.14. Merck & Co., Inc.
    • 13.1.15. Sanofi-Aventis Groupe S.A.
    • 13.1.16. Teva Pharmaceutical Industries Ltd.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing